Company: Hebrew University of Jerusalem, BioNanoSim Ltd
Job title: Professor & Chairman
Professor Simon Benita is the Former Director and Member of the Institute for Drug Research and the School of Pharmacy, Faculty of Medicine at The Hebrew University of Jerusalem, where he received his Ph.D. in Pharmacy in 1980. His research is focused on polymeric drug nano- and micro-delivery systems aimed at improving ocular, dermal penetration and drug targeting. Original nanoparticulate carriers for enhanced oral bioavailability of poorly absorbed and highly lipophilic drugs which can be subjected to massive pre-systemic metabolism and P-gp efflux pump effect are currently under investigation.
Prof. Benita formed and supervises a group of 38 M.Sc., 27 Ph.D. students, and 20 post-doctoral fellows in pharmaceutical sciences. He has published 159 research articles and 20 book chapters, edited or co-edited 5 books and been issued 36 issued and pending patents.
Recipient of The Hebrew University Kaye Innovation Award in 2000, 2005, 2014. He is Knight in National Order of Merit, France.
He is the Founder of the Novagali Pharma in Ophthalmology acquired by Santen Co. Japan, 2012 and NanoBioSim ltd (BNS) focusing on innovative nano-carriers as the solution of choice for enhanced oral, ocular and topical delivery to improve drug profile and therapeutic performance.
Peripherally Restricted CB1 Receptor Blockers for the Treatment of the Metabolic Syndrome 11:00 am
Click to see the Full Event Guide for more informationRead more
day: Day One